echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Label error, Bayer recalled nearly 1000 bottles of hemophilia drugs

    Label error, Bayer recalled nearly 1000 bottles of hemophilia drugs

    • Last Update: 2019-07-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Due to the label error in drug packaging, the best-selling hemophilia A drugs in the company need to be recalled immediately Recently, Bayer announced the initiative to recall nearly 1000 bottles of drugs with label problems, and issued a safety warning to the patients involved According to the recall details released by Bayer, there are two drugs involved in the voluntary recall The reason for the recall is that these batches (batch No 27118rk and 27119cg) of drugs were wrongly labeled with the ingredients of the hemophilia drug kogenatefs In fact, jivi, a hemophilia coagulation factor VIII drug, was filled in the bottle Bayer immediately issued a safety warning after discovering the wrong label, saying that there are about 990 bottles of drugs with wrong label in the market, and the company is closely following any adverse reports on the drug In addition, the recall only covers the U.S market Hemophilia A type A is also known as coagulation factor VIII deficiency or classic hemophilia It is a recessive hereditary hemorrhagic disease caused by X-chromosome linkage and coagulation factor VIII abnormality, which occurs in men At present, the standard nursing of hemophilia A is the replacement therapy of coagulation factor VIII, which requires regular infusion and maintenance of sufficient level of VIII in the body to prevent bleeding At present, the half-life of similar products on the market is short, and preventive drugs need to be given frequently, usually every other day or three times a week Jivi can prolong the half-life and retain the biological activity of rFVIII by inserting a cysteine residue (Cys) on the surface of recombinant human coagulation factor VIII and using it as the attachment site of polyethylene glycol (PEG) polymer Although kogenatefs and jivi have been approved to replace the absence of clotting factors in hemophilia patients, the treatment population of the two is different Kogenatefs is approved to treat adult and child patients with hemophilia A A, while jivi is approved to treat adult and adolescent patients over 12 years old who have been previously treated So far, jivi and kogenate are still among the best-selling drugs in Bayer's product line In the first quarter of 2019, the total sales of the two drugs reached $213 million, which was basically the same as that of the same period of 2018, but exceeded the market expectation by 19% In the future, such drugs will face the direct competition and challenge of rapid growth of Roche hemlibra sales This is not the first time Bayer has recalled a large number of drugs due to the wrong drug ingredients In February 2018, Bayer announced the recall of alka seltzer stomach nourishing effervescent tablets More than a month later, Bayer announced another recall of the drug due to packaging problems Reference source: Bayer recall is labeledvials of the mophilia atreatment this article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.